Tower Research Capital (TRC)’s Acumen Pharmaceuticals ABOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.21K | Sell |
3,631
-4,810
| -57% | -$5.58K | ﹤0.01% | 4361 |
|
|
2025
Q1 | $9.29K | Sell |
8,441
-12,183
| -59% | -$13.4K | ﹤0.01% | 3797 |
|
|
2024
Q4 | $35.5K | Buy |
20,624
+16,714
| +427% | +$28.7K | ﹤0.01% | 2790 |
|
|
2024
Q3 | $9.7K | Sell |
3,910
-22,578
| -85% | -$56K | ﹤0.01% | 3844 |
|
|
2024
Q2 | $64.1K | Buy |
26,488
+25,078
| +1,779% | +$60.7K | ﹤0.01% | 2909 |
|
|
2024
Q1 | $5.71K | Sell |
1,410
-27,679
| -95% | -$112K | ﹤0.01% | 4503 |
|
|
2023
Q4 | $112K | Buy |
29,089
+26,961
| +1,267% | +$104K | ﹤0.01% | 2566 |
|
|
2023
Q3 | $8.83K | Sell |
2,128
-1,447
| -40% | -$6.01K | ﹤0.01% | 4297 |
|
|
2023
Q2 | $17.2K | Buy |
3,575
+553
| +18% | +$2.66K | ﹤0.01% | 3492 |
|
|
2023
Q1 | $12K | Sell |
3,022
-250
| -8% | -$993 | ﹤0.01% | 4042 |
|
|
2022
Q4 | $18K | Sell |
3,272
-4,845
| -60% | -$26.7K | ﹤0.01% | 3196 |
|
|
2022
Q3 | $81K | Buy |
8,117
+4,232
| +109% | +$42.2K | ﹤0.01% | 2740 |
|
|
2022
Q2 | $18K | Buy |
3,885
+1,330
| +52% | +$6.16K | ﹤0.01% | 3880 |
|
|
2022
Q1 | $10K | Sell |
2,555
-3,968
| -61% | -$15.5K | ﹤0.01% | 4266 |
|
|
2021
Q4 | $44K | Buy |
6,523
+5,828
| +839% | +$39.3K | ﹤0.01% | 2852 |
|
|
2021
Q3 | $10K | Buy |
+695
| New | +$10K | ﹤0.01% | 4299 |
|